April 21, 2017
The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza
The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union (EU) for Spinraza. The recommendation indicates that Spinraza should be covered for all types of SMA.
Topics: Front Page News
April 11, 2017
The SMA community is eagerly looking forward to next week’s Patient-Focused Drug Development (PFDD) Meeting with the FDA.
Over 400 members of the community are registered to participate in this event. This includes individuals and families affected by SMA, representatives from...
April 10, 2017
Cure SMA has awarded a $75,000 research grant to Jean Giacomotto, PhD, at the University of Queensland, for his project, "Zebrafish models of Spinal Muscular Atrophy optimized for chemical genetics and drug discovery. From proof-of-principle to new insights and treatments".
In SMA, the...